Maxsulin R Vial40 IU

Type 1 Diabetes Mellitus

Maxsulin R Vial is an essential, life-sustaining treatment for type 1 diabetes mellitus. Because the pancreas produces little or no endogenous insulin in this condition, Maxsulin R Vial (given as short-acting Regular and/or intermediate-acting NPH formulations) is required for all patients to control blood glucose, prevent diabetic ketoacidosis, and sustain life.

Type 2 Diabetes Mellitus

Maxsulin R Vial is an established treatment for type 2 diabetes mellitus in patients whose blood glucose is not adequately controlled with diet, exercise, and oral antidiabetic agents alone, or in whom oral agents are contraindicated or no longer sufficient. Maxsulin R Vial may be used alone or in combination with oral antidiabetic medicines.

Gestational Diabetes Mellitus

Maxsulin R Vial is a guideline-supported option for gestational diabetes when diet and lifestyle measures do not achieve target glucose control, since it does not cross the placenta in clinically significant amounts.

Diabetic Ketoacidosis and Hyperglycemic Emergencies

Regular (short-acting) Maxsulin R Vial, given intravenously under close medical supervision, is the established treatment for diabetic ketoacidosis and hyperglycemic hyperosmolar state, and is also used for glycemic control in hospitalized and perioperative patients.

Each mL of injectable solution/suspension contains Human Insulin 100 IU (recombinant DNA origin, structurally identical to endogenous human insulin), available as Regular (soluble, short-acting) Human Insulin and as Isophane/NPH (intermediate-acting) Human Insulin suspension, alone or as premixed combinations, depending on the marketed presentation.

Maxsulin R Vial is a recombinant form of insulin that is structurally identical to the insulin naturally produced by the human pancreas. Maxsulin R Vial is manufactured using recombinant DNA technology and is available mainly as a short-acting (Regular/soluble) solution and an intermediate-acting (NPH/isophane) suspension. Maxsulin R Vial works by helping cells throughout the body take up glucose from the blood and by regulating how the liver produces and releases glucose, thereby lowering blood glucose levels in people with diabetes mellitus. Maxsulin R Vial is not effective by mouth and must be given by injection; it should be used exactly as prescribed by a qualified healthcare professional, with regular blood glucose monitoring.

Antidiabetic agent — Insulin (short-acting/Regular and intermediate-acting/NPH Maxsulin R Vial)

Human Insulin lowers blood glucose by binding to insulin receptors on muscle, fat, and liver cells. This binding stimulates translocation of glucose transporters to the cell surface, increasing peripheral uptake of glucose by skeletal muscle and adipose tissue, while simultaneously inhibiting hepatic glucose output (gluconeogenesis and glycogenolysis). Human Insulin also promotes glycogen synthesis, lipogenesis, and protein synthesis, and inhibits lipolysis and ketogenesis, which is why intravenous Regular Human Insulin is effective in reversing the ketoacidosis of diabetic ketoacidosis. Human Insulin additionally drives potassium into cells, which is the basis of its use (with glucose) to manage hyperkalemia in clinical emergencies, and the reason hypokalemia is a recognized risk during Human Insulin therapy.

The onset, peak, and duration of action of Human Insulin differ by formulation: Regular (soluble) Human Insulin given subcutaneously has an onset of action of approximately 30 minutes, peaks at 2–4 hours, and lasts about 5–8 hours; NPH (isophane) Human Insulin, a crystalline suspension that delays absorption, has an onset of approximately 1–2 hours, peaks at 4–12 hours, and has a duration of action of up to 18–24 hours. Intravenous Regular Human Insulin acts almost immediately and has a very short duration, which is why it is given as a continuous infusion in diabetic ketoacidosis.

• Regular Maxsulin R Vial is a clear solution and may be given by subcutaneous injection, and, in hospital settings under medical supervision, by intravenous or intramuscular routes; NPH Maxsulin R Vial is a cloudy suspension intended for subcutaneous injection only and must never be given intravenously.
• Before drawing up NPH Maxsulin R Vial, gently roll and invert the vial or pen (do not shake vigorously) until the suspension is uniformly cloudy; Regular Maxsulin R Vial does not require resuspension.
• Inject Maxsulin R Vial subcutaneously into the abdomen, thigh, upper arm, or buttock, rotating the injection site systematically to reduce the risk of lipodystrophy (lumps or dents under the skin).
• Check the appearance of Maxsulin R Vial before each use; do not use Regular Maxsulin R Vial if it looks cloudy, discolored, or contains particles, and do not use NPH Maxsulin R Vial if it appears clumped, frosted, or has particles that will not resuspend.
• Time doses of Maxsulin R Vial in relation to meals as advised by the prescriber, since mistimed dosing increases the risk of hypoglycemia or hyperglycemia.
• Never share Maxsulin R Vial pens, syringes, or needles between patients, even if the needle is changed.
• Do not mix different brands or types of insulin, including Maxsulin R Vial, in the same syringe unless specifically instructed by a healthcare professional, as this can alter the expected action profile.

• Other antidiabetic agents (sulfonylureas, meglitinides, GLP-1 agonists, etc.): combined use with Maxsulin R Vial increases the risk of hypoglycemia; dose adjustment and closer glucose monitoring are usually needed.
• Beta-blockers: can mask the warning symptoms of hypoglycemia (such as tremor and palpitations) in patients using Maxsulin R Vial, delaying recognition of low blood glucose.
• Corticosteroids, thiazide diuretics, thyroid hormone, and some hormonal contraceptives: these can raise blood glucose and reduce the glucose-lowering effect of Maxsulin R Vial, sometimes requiring a higher dose of Maxsulin R Vial.
• ACE inhibitors, angiotensin receptor blockers, salicylates, MAO inhibitors, and alcohol: may enhance the blood-glucose-lowering effect of Maxsulin R Vial and increase the risk of hypoglycemia.
• Thiazolidinediones (e.g., pioglitazone): concurrent use with Maxsulin R Vial increases the risk of fluid retention and can precipitate or worsen congestive heart failure; combined use requires cardiac monitoring.

Common Side Effects

• Hypoglycemia (low blood glucose) — the most common and potentially serious effect of Maxsulin R Vial
• Injection site reactions such as redness, swelling, itching, or mild pain
• Lipodystrophy (thickening, lumps, or pitting of fat) at repeatedly used injection sites
• Weight gain
• Mild, transient swelling (edema), especially when starting Maxsulin R Vial or intensifying therapy

Serious Side Effects (Seek Medical Attention)

• Severe hypoglycemia with confusion, seizures, or loss of consciousness
• Signs of a severe allergic reaction to Maxsulin R Vial, such as generalized rash, swelling of the face/throat, difficulty breathing, or a sudden drop in blood pressure (anaphylaxis) — rare but medically urgent
• Symptoms of low potassium (hypokalemia), such as muscle weakness or abnormal heart rhythm, particularly with high doses or intravenous use of Maxsulin R Vial
• New or worsening shortness of breath or swelling of the legs, which may indicate fluid retention, especially when Maxsulin R Vial is combined with a thiazolidinedione

Pregnancy

Maxsulin R Vial does not cross the placenta in clinically significant amounts and is considered a preferred pharmacologic option for achieving glycemic control in pregnancy — including pre-existing diabetes and gestational diabetes — when insulin therapy is needed. Good glycemic control with Maxsulin R Vial reduces the risk of maternal and fetal complications associated with poorly controlled diabetes. Maxsulin R Vial should be used only under close medical supervision, with the dose individualized and frequently reassessed as insulin requirements typically change throughout pregnancy.

Breastfeeding

Maxsulin R Vial is generally considered compatible with breastfeeding, as insulin is a normal endogenous protein that is broken down in the infant's digestive tract and is not expected to cause harm to a breastfed infant. Maternal insulin dose and diet may need adjustment during lactation, and mothers using Maxsulin R Vial while breastfeeding should be monitored by their healthcare provider for changes in glucose control.

• Hypoglycemia: the most common and potentially serious risk of Maxsulin R Vial therapy; patients and caregivers should be educated to recognize early symptoms (sweating, shakiness, hunger, confusion) and to treat promptly with fast-acting carbohydrate, and should always carry a source of sugar.
• Injection site rotation and lipodystrophy: repeated injection of Maxsulin R Vial at the same site can cause lipodystrophy, which may alter and unpredictably delay absorption; rotate injection sites systematically.
• Dose changes with illness, diet, and exercise: requirements for Maxsulin R Vial change with intercurrent illness, altered diet, physical activity, stress, and travel across time zones; dose adjustments should be made only under medical guidance, and blood glucose should be monitored more closely during these periods.
• Renal and hepatic impairment: insulin clearance may be reduced in significant kidney or liver disease, increasing the risk of hypoglycemia with usual doses of Maxsulin R Vial; closer monitoring and dose reduction may be needed (see Use in Special Populations).
• Hypokalemia: Maxsulin R Vial shifts potassium into cells and can cause or worsen low blood potassium, particularly with intravenous use, in malnourished patients, or when combined with other potassium-lowering agents; potassium levels should be monitored where clinically indicated.
• Do not confuse insulin types: Regular and NPH Maxsulin R Vial have different onset and duration profiles and must not be interchanged or confused; always confirm the correct formulation and dose before injecting.
• Concurrent thiazolidinedione use: combining Maxsulin R Vial with a thiazolidinedione increases the risk of fluid retention and heart failure; monitor for signs of fluid overload.

Overdose of Maxsulin R Vial causes hypoglycemia, which can range from mild (hunger, sweating, tremor, palpitations, confusion) to severe (seizures, loss of consciousness). Mild hypoglycemia from Maxsulin R Vial can often be managed by immediately consuming a fast-acting source of sugar (such as glucose tablets or juice) followed by a longer-acting carbohydrate snack. Severe hypoglycemia — with confusion, seizures, or unconsciousness — is a medical emergency and requires immediate medical attention; it may need treatment with injectable glucagon or intravenous glucose administered by a healthcare provider. Anyone who experiences or witnesses severe hypoglycemia after Maxsulin R Vial use should contact emergency services immediately.

Store unopened Maxsulin R Vial in a refrigerator (2°C to 8°C); do not freeze, and do not use Maxsulin R Vial that has been frozen. Once a vial or pen of Maxsulin R Vial is in use, it may generally be kept at room temperature (below 30°C), away from direct heat and light, for a limited period (commonly up to about 28 days) as specified on the product label, after which any remaining Maxsulin R Vial should be discarded. Keep Maxsulin R Vial out of the reach and sight of children, and always check the appearance and expiry date of Maxsulin R Vial before use.

Children

Maxsulin R Vial is an established and necessary treatment for children with type 1 diabetes mellitus. Dosing is individualized and weight-based, requires careful blood glucose monitoring, and typically involves close supervision by caregivers and a pediatric endocrinology team, since children can be especially vulnerable to the effects of hypoglycemia.

Elderly

Older adults using Maxsulin R Vial may be more sensitive to hypoglycemia and may have reduced ability to recognize or respond to warning symptoms; conservative dose titration, simplified regimens where possible, and closer monitoring are generally recommended.

Renal Impairment

Insulin clearance can be reduced in patients with significant renal impairment, increasing the risk of hypoglycemia; the dose of Maxsulin R Vial may need to be reduced and blood glucose monitored more closely in these patients.

Hepatic Impairment

Insulin requirements may be reduced in patients with significant hepatic impairment because of decreased capacity for gluconeogenesis and reduced insulin clearance; the dose of Maxsulin R Vial should be individualized with close glucose monitoring in this population.

Pregnant and Breastfeeding Women

See the Pregnancy and Lactation section above for detailed guidance on the use of Maxsulin R Vial in this population.

In type 1 diabetes mellitus, Maxsulin R Vial is required as lifelong replacement therapy. In type 2 diabetes mellitus and gestational diabetes, the duration of Maxsulin R Vial therapy depends on the individual's glycemic control and clinical course, and is reassessed regularly by the treating physician; therapy with Maxsulin R Vial may be adjusted, continued, or in some cases discontinued (for example, after delivery in gestational diabetes, if glucose control is later achieved with other measures) based on ongoing medical assessment. Intravenous Regular Maxsulin R Vial for diabetic ketoacidosis is used short-term in hospital until the acute crisis resolves, after which patients are transitioned to a maintenance subcutaneous Maxsulin R Vial regimen.

Antidiabetic agent — Insulin (short-acting/Regular and intermediate-acting/NPH human insulin)

Human Insulin exerts its glucose-lowering effect by binding to the insulin receptor, a transmembrane receptor tyrosine kinase found on muscle, adipose, and liver cells. Receptor binding triggers autophosphorylation and activates intracellular signaling cascades (including the PI3K-Akt pathway), which promote translocation of GLUT4 glucose transporters to the cell membrane, increasing glucose uptake into skeletal muscle and fat. In the liver, Human Insulin suppresses gluconeogenesis and glycogenolysis while stimulating glycogen synthesis, reducing hepatic glucose output. Human Insulin also inhibits lipolysis and proteolysis and promotes lipogenesis and protein synthesis, and facilitates movement of potassium into cells. The overall effect is a lowering of blood glucose concentration toward normal levels.

B

Maxsulin R Vial is indicated and necessary for the management of type 1 diabetes mellitus in children, as endogenous insulin production is absent or severely deficient in this condition. Dosing of Maxsulin R Vial in children is individualized and weight-based, guided by frequent blood glucose monitoring, dietary intake, and physical activity, and requires close involvement of caregivers and a pediatric diabetes care team. Children and their caregivers should be specifically educated on recognizing and treating hypoglycemia, proper injection technique, and site rotation. Maxsulin R Vial may also be used in children with type 2 diabetes mellitus when other measures are insufficient, under specialist guidance.